To date, enhancing the CXCL9/10/11-CXCR3 chemokine axis by administering recombinant CXCL9/10/11 proteins or using expression vector systems has demonstrated positive outcomes in various pre-clinical tumor models, including skin, lung, kidney, and colon tumors [65,66,67]. The gene discussed is CXCR3; the disease is neoplasm.